



ASX Announcement

30 July 2025

Cambium Bio Raises A\$2.12 Million via Fully-Subscribed Placement

Sydney, Australia; 30 July 2025: Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium** or **Company**), a clinical-stage regenerative medicine company focused on ophthalmology and tissue repair, is pleased to announce that it has secured firm commitments to raise A\$2,119,418 through the placement of 4,570,667 new fully-paid ordinary shares utilising the Company's existing 15% placement capacity under ASX Listing Rule 7.1 and additional 10% capacity under Listing Rule 7.1A (Placement).

Key Highlights

Item	Detail
Total funds raised	A\$2,119,418
Shares issued	4,570,667 at A\$0.4637 per share
Lead investor	Da Jyun Capital Investment Corporation (DJCIC) — subscribed for 4,455,717 shares (A\$2,066,116)
Directors' participation	Prof Edmund K. Waller (Chairman) – 60,000 shares; Terence A. Walts (Director) – 54,950 shares *
Pricing	Same valuation as the 5 December 2024 placement; represents a 59.9 % premium to the last closing price (29 July 2025)
Use of proceeds	Initiation of registration-enabling Phase 3 trials for Elate Ocular®, working capital

** Shares subscribed by Prof Waller and Mr Walts are subject to shareholder approval at the upcoming 2025 Annual General Meeting in accordance with ASX Listing Rule 10.11.*

Placement Details

The Placement comprises the issue of 4,570,667 new shares at A\$0.4637 per share, raising A\$2.12 million. Settlement with allotment and normal trading of the new shares is expected in August 2025. Shares issued to DJCIC will rank pari passu with existing ordinary shares. Shares subscribed by Prof Waller and Mr Walts will be issued following shareholder approval at the AGM.

Strategic Investment by DJCIC

Da Jyun Capital Investment Corporation (DJCIC) is a prominent Taiwanese investment firm with deep experience in the regenerative medicine sector across the Asia-Pacific region. DJCIC's cornerstone investment strengthens Cambium Bio's shareholder base with a sophisticated institutional partner well aligned with the Company's strategic objectives.

CEO Commentary

"I am very pleased to attract sophisticated institutional investors, such as DJCIC, with experience in regenerative medicine, to support Cambium Bio as we initiate registration-enabling Phase 3 trials. Investment at a 60 % premium to current trading represents a belief by the independent investors in the intrinsic value of Elate Ocular® and its future potential. With this investment, Cambium Bio will progress to dosing first patients and initiate global licensing discussions with big pharma and other strategic players."

— **Karolis Rosickas, Chief Executive Officer**

- ENDS -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:
Acclime Australia – Company Secretary
Email: info@cambium.bio

Cambium Bio Limited
Unit 2.06/31 Lexington Drive, Bella Vista, NSW 2153 Australia
ABN 13 127 035 358
Phone: 1300 995 098
www.cambium.bio